Literature DB >> 11125186

Granulomatous osteonecrosis in Crohn's disease.

H J Freeman1, D Owen, M Millan.   

Abstract

A 25-year-old white woman was diagnosed with Crohn's disease involving the small and large intestines. She had a complex clinical course that required treatment with multiple pharmacological agents, including intravenous, oral and rectal corticosteroids. She also received parenteral nutrition with lipid emulsions. Finally, repeated intestinal resections and drainage of perianal abscesses were required. Her disease was complicated by gallstones, urolithiasis and hip pain. After osteonecrosis was diagnosed, joint replacements were performed. Review of the pathological sections from the resected hip, however, resulted in detection of granulomatous inflammation with multinucleated giant cells - the histological 'footprint' of Crohn's disease in the gastrointestinal tract. Because prior specialized perfusion fixation pathological studies of the intestine in Crohn's disease have shown that granulomas are located in the walls of blood vessels, a possible mechanism for the pathogenesis of osteonecrosis in Crohn's disease is chronic microvascular ischemia of bone.

Entities:  

Mesh:

Year:  2000        PMID: 11125186     DOI: 10.1155/2000/294195

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  3 in total

1.  Sellar inflammatory mass with inflammatory bowel disease.

Authors:  Hugh J Freeman; John Maguire
Journal:  Can J Gastroenterol       Date:  2010-01       Impact factor: 3.522

Review 2.  Natural history and long-term clinical course of Crohn's disease.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 3.  High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review.

Authors:  Michael A Mont; Robert Pivec; Samik Banerjee; Kimona Issa; Randa K Elmallah; Lynne C Jones
Journal:  J Arthroplasty       Date:  2015-04-08       Impact factor: 4.757

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.